fast peptides FAQ

Reduce fat intake to 20–25% of daily calories and avoid lying down within two hours of eating. High-fat meals compound GLP-1-induced gastric delay. If nausea persists beyond eight weeks at the same dose, contact your prescribing physician to discuss slowing the titration schedule or switching to an alternative GLP-1 formulation with different excipients. Persistent nausea beyond the adjustment period may indicate gallbladder dysfunction, which occurs in 1–2% of patients on GLP-1 therapy and requires medical evaluation.

Plateaus occur when caloric intake gradually creeps upward to match the new, lower appetite threshold. The peptide suppresses hunger, but it doesn't prevent overeating if food is hyperpalatable or calorically dense. Track total daily calories for one week using a food scale and diary. Most plateau patients discover they're consuming 200–400 more calories daily than they estimate. Adjust macronutrient ratios to increase protein to 35–40% of total intake and reduce carbohydrates to 30–35%, which improves satiety per calorie consumed.

The STEP 1 Extension trial found participants regained approximately two-thirds of lost weight within one year of stopping semaglutide. This isn't medication failure. It reflects the return of baseline hormonal signaling when GLP-1 agonism is removed. For patients who achieve goal weight and wish to discontinue, transition to a lower maintenance dose (0.5–1.0mg weekly for semaglutide) rather than stopping abruptly. Pair this with continued dietary structure, resistance training three times weekly, and regular metabolic monitoring (quarterly HbA1c and fasting glucose).

Your body has adapted to the dose. GLP-1 receptor density downregulates over time. This is why clinical titration schedules increase dose every 4 weeks rather than starting at therapeutic levels. If you've been at the same dose for 8–12 weeks and weight loss has stalled, the standard response is to increase dose incrementally. Alternatively, switching to a dual agonist like Mazdutide or Survodutide activates the glucagon pathway, which GLP-1-only compounds don't target. Plateaus are metabolic adaptation, not medication failure.

You'll still lose weight. But primarily through appetite suppression, not metabolic reprogramming. GLP-1 agonists delay gastric emptying and suppress ghrelin, which reduces caloric intake passively. The STEP-1 trial showed 14.9% mean weight loss with semaglutide even without structured dietary intervention. However, patients who maintained a structured caloric deficit alongside GLP-1 therapy lost 2–3× more visceral fat than those relying on the medication alone, because the combination shifts substrate partitioning toward fat oxidation rather than just reducing intake.

You target two distinct pathways. Appetite suppression plus direct lipolysis. This is common in research settings but requires careful monitoring because GLP-1 slows gastric emptying while GH increases insulin resistance transiently. The result can be delayed glucose absorption combined with reduced insulin sensitivity, leading to postprandial hyperglycemia. If you're exploring this combination, fasting glucose and HbA1c should be tracked weekly during the first month. Anecdotally, researchers report faster visceral fat loss but higher rates of nausea and GI distress during dose titration.